Zobrazeno 1 - 10
of 135
pro vyhledávání: '"J M Nabholtz"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
N. Chalabi, K.E. Benmammar, V. Servent, Sharif Kullab, Xavier Durando, I. van Praagh, Anne Cayre, Fabrice Kwiatkowski, Y-J Bignon, Nina Radosevic-Robin, M.M. Dauplat, Catherine Abrial, J.P. Jacquin, J-M Nabholtz, Frédérique Penault-Llorca, Ph. Chollet, Marie-Ange Mouret-Reynier, M.R.K. Bahadoor
Publikováno v:
International Journal of Cancer. 138:2274-2280
Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) is overexpressed in around 50% of TNBC and may play a role in its pathogenesis. Consequently, we performed a multice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118b2865724f80ed889ac2438b8de110
https://doi.org/10.1002/ijc.29952
https://doi.org/10.1002/ijc.29952
Autor:
Anne Cayre, Catherine Abrial, Frédérique Penault-Llorca, M.M. Dauplat, N. Chalabi, F Maury, Fabrice Kwiatkowski, Nina Radosevic-Robin, M. Roche, J-M Nabholtz, M.-A. Mouret-Reynier
Publikováno v:
Cancer Research. 73:P5-08
Background: Our group has previously reported (SABCS 2012, abstract 1081) a 2-fold higher pathologic complete response (pCR) rate in TNBC treated with panitumumab+FEC100 (47%) than with the standard therapy alone. However, in a half of the patients (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6936f5d2b6bf631a546dc3e1b4448ab7
https://doi.org/10.1158/0008-5472.sabcs13-p5-08-07
https://doi.org/10.1158/0008-5472.sabcs13-p5-08-07
Autor:
I. van Praagh, Catherine Abrial, Frédérique Penault-Llorca, Anne Cayre, Y-J Bignon, Nina Radosevic-Robin, Yannick Bidet, J.P. Jacquin, J-M Nabholtz, F Kwiatkoswki, A-V Bourcier, P. Chollet, N. Chalabi, F Del Piano, M.M. Dauplat, B. Nayl, V. Servent, Pascale Dubray-Longeras, M-A Mouret-Reynier, Nancy Uhrhammer
Publikováno v:
Cancer Research. 73:P1-08
Background: TNBC is a heterogenous group of tumors for some of which the Epithelial Growth Factor Receptor pathway (EGFR) may play an important role. We evaluated the efficacy and toxicity of an anti-EGFR antibody (cetuximab) combined with docetaxel,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cd3feebc12f5d859a65a6111550c0c1
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-34
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-34
Autor:
Nancy Uhrhammer, Fabrice Kwiatkowski, Catherine Abrial, Olivier Tredan, Cecile Aube, Alexis Desrichard, M-A Mouret-Reynier, Y-J Bignon, Nina Radosevic-Robin, J-M Nabholtz, Anne Cayre, P. Chollet, M.M. Dauplat, Bettina Weber, N. Chalabi, Joseph Gligorov, Maud Privat, P. Romero, Yannick Bidet, Frédérique Penault-Llorca
Publikováno v:
Cancer Research. 73:P3-14
Background: Panitumumab is an antibody targeting the epidermal growth factor receptor (EGFR) for which an important role has been suggested in TNBC. Consequently, we evaluated a combination of the standard chemotherapy (FEC 100 followed by docetaxel)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33df3b8bf9ca73401a0ebf184060d7ac
https://doi.org/10.1158/0008-5472.sabcs13-p3-14-19
https://doi.org/10.1158/0008-5472.sabcs13-p3-14-19
Autor:
J.-M. Nabholtz, Markus F. Renschler, Javier Cortes, Debora Barton, Amy Ko, Stefan Glück, Joyce O'Shaughnessy, Denise A. Yardley, Robert E. Coleman, Robert Beck, Pierfranco Conte, Nadia Harbeck, Adam Brufsky
Publikováno v:
Trials. 17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f2f742e9820132a3c119cde3524159
https://doi.org/10.1186/s13063-016-1195-6
https://doi.org/10.1186/s13063-016-1195-6
Autor:
N. Chalabi, Joseph Gligorov, Nancy Uhrhammer, Frédérique Penault-Llorca, Laurence Vanlemmens, Christelle Jouannaud, Bettina Weber, M-A Mouret-Reynier, Maud Privat, J-M Nabholtz, Fabrice Kwiatkowski, Anne Cayre, P. Chollet, Séverine Guiu, Thierry Petit, Catherine Abrial, Alexis Desrichard, Olivier Tredan, M.M. Dauplat, Nicole Tubiana-Mathieu
Publikováno v:
Cancer Research. 72:P3-06
Background: TNBC is an heterogeneous group of tumors for some of which the Epithelial Growth Factor Receptor pathway (EGFR) may play an important role. We evaluated the efficacy and toxicity of an anti-EGFR antibody (panitumumab) combined with a stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05a653bb5c5b43dc17c4d0765fd9260a
https://doi.org/10.1158/0008-5472.sabcs12-p3-06-20
https://doi.org/10.1158/0008-5472.sabcs12-p3-06-20
Autor:
Joseph Gligorov, Praagh-Doreau I Van, Nicole Tubiana-Mathieu, Christelle Jouannaud, M-A Mouret-Reynier, Frédérique Penault-Llorca, Laurence Vanlemmens, B. Nayl, Bettina Weber, F Mayer, H Devaud, Pascale Dubray-Longeras, J. P. Ferriere, Eloise Planchat, Thierry Petit, N. Chalabi, Fabrice Kwiatkowski, J-M Nabholtz, P. Chollet, Catherine Abrial, Olivier Tredan
Publikováno v:
Cancer Research. 71:P3-14
Background: Panitumumab is an antibody targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC 100 followed by T) with panitumumab as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f25b5d2b5ddf626dbcf079ef5e8e5800
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
Autor:
Praagh-Doreau I Van, Emilie Thivat, Qian Wang-Lopez, Inès Raoelfils, Catherine Abrial, Frédérique Penault-Llorca, J-M Nabholtz, M-A Mouret-Reynier, P. Chollet, Xavier Durando, P. Gimbergues
Publikováno v:
Cancer Research. 71:P5-14
Purpose of the study: In a new database harbouring the patients of several prospective phase II neoadjuvant trials (fec 50–100, net, tncf, taxotere/tncf, taxotere alone), the predictive value of tumour factors (SBR grade, RH, Her2, Ki-67 and cyclin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69a819f1b10764dc9addd12856ea87c7
https://doi.org/10.1158/0008-5472.sabcs11-p5-14-20
https://doi.org/10.1158/0008-5472.sabcs11-p5-14-20
Autor:
C. Dabot, N. Oger, A. Kacher, S. Irrmann, B. Dib, J. P. Colloc, N. Chalabi, J. M. Nabholtz, I. Lorenzi, A. M. Forest, S. Meunier, V. Da Costa, I. Jeudy
Publikováno v:
Oncologie. 13:295-302
Le Plan cancer 2 lance en novembre 2009 par l’Institut national du cancer (INCa) met en avant la volonte de renforcer l’accompagnement du patient atteint de cancer non seulement lors de la phase active de traitement, le pendant, mais aussi lors d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93c5b46b513bf072851ef1e0ed91ab69
https://doi.org/10.1007/s10269-011-2025-9
https://doi.org/10.1007/s10269-011-2025-9